COP chemotherapy is treatment to cure multiple myeloma and chronic lymphocytic leukemia. COP chemotherapy is combination chemotherapy in which three chemotherapy drugs including cyclophosphamide, vincristine sulfate and prednisone are used to eradicate cancer.
COP chemotherapy is used as myeloma chemotherapy treatment. Single drug chemotherapy is not effective in treating chronic lymphocytic leukemia. Therefore combination chemotherapy regimen is applied to treat advanced leukemia patients with increasing adenopathy, splenomegaly and anemia. Combination chemotherapy used is known as COP chemotherapy. It includes cyclophosphamide, vincristine sulfate, and prednisone for treating patients with chronic lymphocytic leukemia. COP is an effective and well-tolerated therapy for advanced chronic lymphocytic leukemia.
COP chemotherapy is also used to treat multiple myeloma. Before the using alkylating agents in chemotherapy for treating multiple myeloma, survival period of patient was very less (less than 1 year). Before COP chemotherapy, combination of melphalan and prednisone is the standard regimen for multiple myeloma for more than two decades with median survival ranging from two to three years. When COP chemotherapy is used to treat multiple myeloma, it is more effective than MP (melphalan and prednisone) chemotherapy. Cyclophosphamide has therapeutic activity in treating multiple myeloma and vincristine is an effective agent in the treatment.
COP Chemotherapy Administration
COP chemotherapy is mostly used when the single chemotherapy drug is not able to treat a particular type of cancer. This treatment is given in cycles, which are usually repeated after every seven weeks. The patients are given a break of several days in between two cycles so that it would allow the patient to recover from the side effects of this treatment. There are a few chemotherapy drugs side effects which can be managed easily.
The name COP is derived from the initial letters, which is taken from the drugs, such as cyclophosphamide, vincristine and prednisone, which are used for the treatment. These drugs are given along with the drugs whose combination is known as BLAM. It involves the combination of the drugs such as bleomycin, doxorubicin, and procarbazine. This combination chemotherapy is used for treating the large cell lymphoma.
During COP-BLAM IA and IB chemotherapy, drugs are easily administered on an outpatient basis, which produces complete remissions with long term, disease free survival. COP-BLAM III is an outgrowth of studies of infusional therapy. COD-BLAM IV chemotherapy treats patients four sequential cycles of infusional chemotherapy. In this treatment, high-dose alternating myelosuppressive drugs (doxorubicin, cyclophosphamide), and cycle-active agents (methotrexate, cytarabine, and etoposide) are used. While in COP-BLAM V chemotherapy, four to six sequential cycles of infusional chemotherapy are applied to increase the rapidity of response. Though COP-BLAM IV chemotherapy treatment is shortened, it is very effective. However, the effectiveness of COP chemotherapy also depends on age, prognosis and overall health of the patient.